Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.68 |
| ▸ | TACR1 | P25103 | 6/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetyltryptophanamide SCHEMBL22850012 | 1.00 | ECE1 (0.68) | ECE1TACR1ALOX15HPGDSKMT2A | |
| Acetyltryptophanamide SCHEMBL455277 | 1.00 | ECE1 (0.68) | ECE1TACR1ALOX15HPGDSKMT2A | |
| SCHEMBL24122594 | 0.95 | ECE1 (0.69) | ECE1TACR1ALOX15KMT2AACE | |
| SCHEMBL30493767 | 0.95 | ECE1 (0.69) | ECE1TACR1ALOX15KMT2AACE | |
| SCHEMBL13176572 | 0.92 | TACR1 (0.67) | TACR1ALOX15KMT2AACEBCL2A1 | |
| SCHEMBL5747459 | 0.92 | TACR1 (0.67) | TACR1ALOX15KMT2AACEBCL2A1 | |
| SCHEMBL26511911 | 0.90 | CCKBR (0.64) | ECE1 | |
| SCHEMBL26511568 | 0.90 | CCKBR (0.64) | ECE1 | |
| SCHEMBL14213192 | 0.89 | ECE1 (0.67) | ECE1ALOX15HPGDSKMT2AACE | |
| Acetyltryptophanamide SCHEMBL4654401 | 0.89 | TACR1 (0.63) | ECE1TACR1ALOX15HPGDSKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618077-B2 | Compositions and methods for treating fragile X premutation RVGG repeats-mediated toxicity | EMORY UNIVERSITY (US) | 2013-12-31 | — | — | US | claimed |
| US-20120277178-A1 | COMPOSITIONS AND METHODS FOR TREATING FRAGILE X PREMUTATION RVGG REPEATS-MEDIATED TOXICITY | EMORY UNIVERSITY (US) | 2012-11-01 | — | — | US | claimed |
| EP-1428537-B1 | STABILIZED PREPARATIONS CONTAINING ANTIBODY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-11-19 | — | — | EP | claimed |
| WO-2024059119-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | SOLIOME, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117120476-A | Antibodies specific for structurally disordered sequences | XL-普洛坦公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114072206-A | Method of treatment | 沃卢申伊缪诺制药公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-110896606-A | COVERSIN for the treatment of autoimmune vesiculopathy | 沃卢申伊缪诺制药公司 | 2020-03-20 | — | — | CN | disclosed |
| CN-110831617-A | Coversin for the treatment of cicatricial ocular inflammatory disorders | 沃卢申伊缪诺制药公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110799207-A | Coversin variants lacking C5 binding | 沃卢申伊缪诺制药公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| CN-1345245-A | Apolipoprotein A-I agonists and their use to treat dyslipidemias | JEAN LOUIS DASSEUX (US) | 2002-04-17 | — | — | CN | disclosed |
| EP-1140856-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| CN-1303298-A | Gene therapy methods providing apolipoprotein A-1 agonists and their use to treat lipemia | JEAN LOUIS DASSEUX (US) | 2001-07-11 | — | — | CN | disclosed |
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED (AT) | 2001-06-28 | — | — | US | disclosed |
| US-6207831-B1 | A BENZOPYRAZOLE COMPOUND | NOVARTIS AG (CH) | 2001-03-27 | — | — | US | disclosed |
| CN-1280501-A | Apolipoprotein A-I agonists and their use in the treatment of dyslipidemic disorders | JEAN LOUIS DASSEUX (US) | 2001-01-17 | — | — | CN | disclosed |
| CN-1280500-A | Apolipoprotein A-I agonists and their use in the treatment of dyslipidemic disorders | JEAN LOUIS DASSEUX (US) | 2001-01-17 | — | — | CN | disclosed |
| WO-2000037448-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| US-4066405-A | MOLECULAR SIEVE PROCESS ISOLATES ZINC PROTEIN | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLC43A1, CUTA, ANXA1 | ECE1 1295/4885TACR1 4581/4885ALOX15 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.